Global Antibody-drug Conjugates Supply, Demand and Key Producers, 2026-2032
The global Antibody-drug Conjugates market size is expected to reach $ 39647 million by 2032, rising at a market growth of 13.9% CAGR during the forecast period (2026-2032).
Antibody-drug Conjugates are targeted biopharmaceuticals that combine a monoclonal antibody with a cytotoxic or biologically active payload through a chemical linker. The antibody recognizes a tumor-associated antigen, enabling selective internalization or localized payload release while reducing systemic exposure relative to conventional chemotherapy. Core product attributes include antigen specificity, antibody format, linker stability and cleavage mechanism, payload class and potency, drug-to-antibody ratio, conjugation-site distribution, aggregation level, formulation stability and dosing strength. Commercial products are primarily supplied as intravenous liquid or lyophilized injections for solid tumors and hematologic malignancies. This study focuses on commercial Antibody-drug Conjugates and evaluates the market by payload mechanism, linker type, conjugation technology, target antigen, therapeutic indication and geographic market. Market value is measured primarily through manufacturer-recognized net product sales because vial strengths, body-weight-based dosing, treatment cycles, regional reimbursement and alliance accounting differ materially between products.
Value creation is concentrated in target validation, proprietary linker-payload chemistry, reproducible conjugation, clinical differentiation, regulatory execution and commercial access. Downstream products are distributed through oncology hospitals, specialist treatment centers, authorized pharmaceutical distributors and specialty channels, with payment influenced by indication, patient weight, treatment cycle, vial strength, reimbursement and negotiated discounts. Commercial ADCs can support high product-level gross margins, but development failures, pharmacovigilance, diagnostic support and post-approval trials consume substantial lifecycle investment. Supply reliability and capacity planning therefore remain important competitive factors alongside clinical performance.
Conventional stochastic conjugation remains widely used in marketed products because of established manufacturing experience and regulatory familiarity. However, site-specific and controlled conjugation technologies are attracting greater development investment because they can narrow drug-to-antibody ratio distribution and improve batch consistency. Solid tumors represent the largest application segment, led by breast, urothelial, lung, gynecologic and gastrointestinal cancers. Hematologic malignancies remain an important established segment, especially where validated lineage antigens support efficient internalization and clear patient selection.
Asia-Pacific is developing into the most dynamic regional opportunity. Japan combines established ADC innovation with advanced oncology infrastructure, while China is expanding domestic development, manufacturing capacity, regulatory approvals and commercial partnerships. Chinese products are also increasing licensing activity in international markets, strengthening the region’s role in global innovation rather than only local supply. Other emerging markets offer longer-term demand potential, but access remains constrained by oncology budgets, diagnostic availability, specialist capacity and cold-chain distribution.
This report is a detailed and comprehensive analysis of the world market for Antibody-drug Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antibody-drug Conjugates that contribute to its increasing demand across many markets.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Antibody-drug Conjugates market
2. What is the demand of the global Antibody-drug Conjugates market?
3. What is the year over year growth of the global Antibody-drug Conjugates market?
4. What is the total value of the global Antibody-drug Conjugates market?
5. Who are the Major Players in the global Antibody-drug Conjugates market?
6. What are the growth factors driving the market demand?
Antibody-drug Conjugates are targeted biopharmaceuticals that combine a monoclonal antibody with a cytotoxic or biologically active payload through a chemical linker. The antibody recognizes a tumor-associated antigen, enabling selective internalization or localized payload release while reducing systemic exposure relative to conventional chemotherapy. Core product attributes include antigen specificity, antibody format, linker stability and cleavage mechanism, payload class and potency, drug-to-antibody ratio, conjugation-site distribution, aggregation level, formulation stability and dosing strength. Commercial products are primarily supplied as intravenous liquid or lyophilized injections for solid tumors and hematologic malignancies. This study focuses on commercial Antibody-drug Conjugates and evaluates the market by payload mechanism, linker type, conjugation technology, target antigen, therapeutic indication and geographic market. Market value is measured primarily through manufacturer-recognized net product sales because vial strengths, body-weight-based dosing, treatment cycles, regional reimbursement and alliance accounting differ materially between products.
Key Findings
- Global Antibody-drug Conjugate shipments reached approximately 6.0 million standard vial equivalents in 2025
- The weighted average manufacturer selling price was approximately USD 2,580 per standard vial equivalent in 2025
- More than 15 Antibody-drug Conjugates had entered commercial use across major markets by 2025
- North America remains the largest regional market supported by rapid launch uptake and premium oncology reimbursement
- Solid tumors have become the principal demand base while hematologic malignancies retain established clinical positions
- Topoisomerase I inhibitor payloads and cleavable linkers are driving the fastest product expansion
Market Trends
Antibody-drug Conjugates are evolving from relatively heterogeneous first-generation products toward more stable, homogeneous and therapeutically differentiated platforms. Development priorities are shifting from late-line hematologic indications to larger solid-tumor populations, earlier treatment lines and biomarker-defined pan-tumor opportunities. New products increasingly use highly potent topoisomerase I inhibitors, optimized cleavable linkers and controlled drug-to-antibody ratios to strengthen bystander activity while managing systemic toxicity. Site-specific conjugation, biparatopic or bispecific antibodies, dual-payload architectures and immune-stimulating payloads represent the next layer of product innovation, although their manufacturing and regulatory requirements remain demanding. At the clinical level, combination regimens with immune checkpoint inhibitors and other targeted therapies are expanding the addressable population. Companion diagnostics, quantitative antigen testing and resistance monitoring are consequently becoming more important to patient selection, treatment sequencing and lifecycle management.Market Dynamics
Drivers
Market expansion is being driven by the broadening of approved indications, movement into earlier treatment lines and continued validation of ADCs in major solid tumors. Successful products have demonstrated that an effective antibody, linker and payload combination can improve clinical outcomes in patients with limited alternatives, supporting physician adoption and premium oncology pricing. Pharmaceutical companies are increasing internal development, licensing and co-development investment because a validated ADC platform can generate multiple target-specific candidates. Growth is also reinforced by improved biomarker testing, expansion of oncology treatment infrastructure and increasing regulatory acceptance of ADCs across North America, Europe and Asia.Restraints
ADC development and production involve substantially greater complexity than conventional monoclonal antibodies. Manufacturers must coordinate antibody production, high-potency payload synthesis, linker chemistry, conjugation, purification, aseptic filling and specialized analytical testing under tightly controlled conditions. Payload containment requirements, limited qualified capacity, long production lead times and low initial batch volumes increase unit costs. Commercial adoption may also be constrained by treatment-related toxicities, dose interruptions, regional reimbursement negotiations and the need for specialized infusion and adverse-event management. These factors can delay penetration even after regulatory approval.Opportunities
The most attractive opportunities are emerging from new tumor targets, improved therapeutic windows and expansion beyond heavily pretreated patients. Targets such as B7-H3, HER3, CLDN18.2, c-MET and other tumor-associated antigens offer room for differentiated products, particularly where existing therapies provide limited durability. Further opportunities exist in earlier-stage disease, perioperative treatment, biomarker-defined pan-tumor indications and rational combinations with immunotherapy. Asia-Pacific offers additional potential through local clinical development, regional licensing, domestic manufacturing and broader reimbursement access. Platform suppliers and specialized contract manufacturers can also benefit as developers seek external capacity for payload production, conjugation and high-potency fill-finish operations.Challenges
The principal challenge is maintaining a sufficiently wide therapeutic index while preserving strong antitumor activity. Antigen heterogeneity, variable internalization, payload resistance, linker instability and off-target toxicity can weaken clinical differentiation or limit dose intensity. Developers must also demonstrate superiority against rapidly changing standards of care, requiring larger and more expensive comparative trials. Intellectual-property overlap across antibodies, linkers, payloads and conjugation methods increases freedom-to-operate risk. Commercially, companies face indication crowding, pricing scrutiny and the possibility that competing ADCs, bispecific antibodies, radioligand therapies or other targeted modalities will reduce the value of late-entry products.Industry Chain Analysis
The upstream ADC industry chain comprises monoclonal antibody cell lines and biologic drug substance, linker intermediates, highly potent payloads, conjugation reagents, chromatography resins, single-use processing systems and analytical materials. Payload and linker production require advanced organic synthesis, containment and impurity control, while antibody production relies on mature mammalian-cell bioprocessing. Midstream activities integrate antibody manufacture with conjugation, purification, formulation, sterile filling, quality testing and cold-chain release. Process consistency is critical because changes in drug-to-antibody ratio, free payload, aggregation or conjugation-site distribution can materially affect efficacy, safety and shelf life.Value creation is concentrated in target validation, proprietary linker-payload chemistry, reproducible conjugation, clinical differentiation, regulatory execution and commercial access. Downstream products are distributed through oncology hospitals, specialist treatment centers, authorized pharmaceutical distributors and specialty channels, with payment influenced by indication, patient weight, treatment cycle, vial strength, reimbursement and negotiated discounts. Commercial ADCs can support high product-level gross margins, but development failures, pharmacovigilance, diagnostic support and post-approval trials consume substantial lifecycle investment. Supply reliability and capacity planning therefore remain important competitive factors alongside clinical performance.
Segment Insights
By payload mechanism, microtubule inhibitors retain a substantial installed commercial base through established products, while topoisomerase I inhibitors are gaining strategic importance because of their activity in solid tumors and potential bystander effect. DNA-damaging payloads remain important in selected hematologic indications but represent a narrower commercial segment. Cleavable linkers increasingly dominate newer product development because they facilitate intracellular or tumor-microenvironment payload release, whereas non-cleavable linkers retain relevance where plasma stability and controlled intracellular processing are prioritized.Conventional stochastic conjugation remains widely used in marketed products because of established manufacturing experience and regulatory familiarity. However, site-specific and controlled conjugation technologies are attracting greater development investment because they can narrow drug-to-antibody ratio distribution and improve batch consistency. Solid tumors represent the largest application segment, led by breast, urothelial, lung, gynecologic and gastrointestinal cancers. Hematologic malignancies remain an important established segment, especially where validated lineage antigens support efficient internalization and clear patient selection.
Downstream Market Opportunities
The largest downstream opportunity lies in expanding ADCs from salvage therapy into earlier treatment lines and curative-intent settings. Breast cancer remains a major commercial foundation, while urothelial, lung, ovarian, cervical, gastric and other biomarker-defined solid tumors are creating additional demand. Treatment centers increasingly require integrated diagnostic testing, standardized toxicity-management pathways and dependable product availability rather than drug supply alone. Opportunities are also emerging from community oncology adoption, combination regimens and broader testing of low or heterogeneous antigen expression. Products that demonstrate clinically meaningful survival benefits, manageable adverse events and practical dosing schedules are better positioned to secure formulary access and sustained physician use.Regional Insights
North America remains the largest Antibody-drug Conjugates market because the United States combines early regulatory launches, concentrated oncology expertise, broad biomarker testing and relatively high net drug prices. Commercial uptake can be rapid when an ADC receives a differentiated label or moves into an earlier treatment line, although payer controls and indication-specific reimbursement are becoming more influential. Europe represents a major but more price-controlled market, with country-level health technology assessment, reimbursement timing and treatment guidelines producing uneven launch curves.Asia-Pacific is developing into the most dynamic regional opportunity. Japan combines established ADC innovation with advanced oncology infrastructure, while China is expanding domestic development, manufacturing capacity, regulatory approvals and commercial partnerships. Chinese products are also increasing licensing activity in international markets, strengthening the region’s role in global innovation rather than only local supply. Other emerging markets offer longer-term demand potential, but access remains constrained by oncology budgets, diagnostic availability, specialist capacity and cold-chain distribution.
Competitive Landscape Analysis
Competition is shifting from a small group of early ADC pioneers toward integrated global pharmaceutical portfolios and specialized platform companies. Daiichi Sankyo and AstraZeneca have established a strong position around the DXd platform, while Roche retains an important commercial franchise across solid tumors and hematologic malignancies. Pfizer’s acquisition of Seagen consolidated Padcev, Adcetris and Tivdak within a larger oncology organization, and AbbVie’s acquisition of ImmunoGen brought Elahere and related technology into its portfolio. Gilead, Astellas, GSK, Takeda and ADC Therapeutics compete through marketed products, partnerships or indication expansion. In China, RemeGen and Kelun-Biotech have entered commercial-stage competition, while Hengrui, Hansoh, CSPC, Mabwell, Duality Biologics, MediLink Therapeutics and other developers are advancing differentiated targets and linker-payload platforms. Future leadership will depend less on the number of pipeline candidates and more on clinical differentiation, manufacturing reproducibility, biomarker strategy, global regulatory execution, market access and the ability to manage combination development across multiple indications.Report Scope
This report studies the global Antibody-drug Conjugates demand, key companies, and key regions.This report is a detailed and comprehensive analysis of the world market for Antibody-drug Conjugates, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Antibody-drug Conjugates that contribute to its increasing demand across many markets.
Highlights and key features of the study
- Global Antibody-drug Conjugates total market, 2021-2032, (USD Million)
- Global Antibody-drug Conjugates total market by region & country, CAGR, 2021-2032, (USD Million)
- U.S. VS China: Antibody-drug Conjugates total market, key domestic companies, and share, (USD Million)
- Global Antibody-drug Conjugates revenue by player, revenue and market share 2021-2026, (USD Million)
- Global Antibody-drug Conjugates total market by Type, CAGR, 2021-2032, (USD Million)
- Global Antibody-drug Conjugates total market by Application, CAGR, 2021-2032, (USD Million)
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Antibody-drug Conjugates market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.Global Antibody-drug Conjugates Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
Market Segmentation
Global Antibody-drug Conjugates Market, Segmentation by Type:
- HER2-Directed ADCs
- TROP2-Directed ADCs
- Hematologic-Lineage Antigen ADCs
- Other Target Antigen ADCs
Global Antibody-drug Conjugates Market, Segmentation by Payload Mechanism:
- Topoisomerase I Inhibitor ADCs
- Microtubule Inhibitor ADCs
- DNA-Damaging ADCs
- Other Payload ADCs
Global Antibody-drug Conjugates Market, Segmentation by Drug-To-Antibody Ratio:
- DAR Up To 4
- DAR Above 4 And Below 8
- DAR 8 And Above
- Other
Global Antibody-drug Conjugates Market, Segmentation by Application:
- Breast and Gynecologic Malignancies
- Lung and Other Thoracic Malignancies
- Other Solid Tumors
- Hematologic Malignancies
Companies Profiled:
- Daiichi Sankyo Company, Limited
- Roche
- Pfizer Inc.
- Gilead Sciences, Inc.
- Astellas Pharma Inc.
- AbbVie Inc.
- GSK plc
- ADC Therapeutics SA
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
- Genmab A/S
- Johnson & Johnson
- Merck & Co., Inc.
- MacroGenics, Inc.
- Sutro Biopharma, Inc.
- Heidelberg Pharma AG
- RemeGen Co., Ltd.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Innovent Biologics, Inc.
- CSPC Pharmaceutical Group Limited
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Lepu Biopharma Co., Ltd.
- Duality Biologics (Shanghai) Co., Ltd.
- MediLink Therapeutics (Suzhou) Co., Ltd.
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Hangzhou DAC Biotechnology Co., Ltd.
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
- Sichuan Biokin Pharmaceutical Co., Ltd.
- Bio-Thera Solutions, Ltd.
Key Questions Answered
1. How big is the global Antibody-drug Conjugates market?2. What is the demand of the global Antibody-drug Conjugates market?
3. What is the year over year growth of the global Antibody-drug Conjugates market?
4. What is the total value of the global Antibody-drug Conjugates market?
5. Who are the Major Players in the global Antibody-drug Conjugates market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Antibody-drug Conjugates Introduction
1.2 World Antibody-drug Conjugates Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Antibody-drug Conjugates Total Market by Region (by Headquarter Location)
1.3.1 World Antibody-drug Conjugates Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.3 China Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.4 Europe Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.5 Japan Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.6 South Korea Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.7 ASEAN Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.8 India Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Antibody-drug Conjugates Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Antibody-drug Conjugates Consumption Value (2021-2032)
2.2 World Antibody-drug Conjugates Consumption Value by Region
2.2.1 World Antibody-drug Conjugates Consumption Value by Region (2021-2026)
2.2.2 World Antibody-drug Conjugates Consumption Value Forecast by Region (2027-2032)
2.3 United States Antibody-drug Conjugates Consumption Value (2021-2032)
2.4 China Antibody-drug Conjugates Consumption Value (2021-2032)
2.5 Europe Antibody-drug Conjugates Consumption Value (2021-2032)
2.6 Japan Antibody-drug Conjugates Consumption Value (2021-2032)
2.7 South Korea Antibody-drug Conjugates Consumption Value (2021-2032)
2.8 ASEAN Antibody-drug Conjugates Consumption Value (2021-2032)
2.9 India Antibody-drug Conjugates Consumption Value (2021-2032)
3 WORLD ANTIBODY-DRUG CONJUGATES COMPANIES COMPETITIVE ANALYSIS
3.1 World Antibody-drug Conjugates Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Antibody-drug Conjugates Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Antibody-drug Conjugates in 2025
3.2.3 Global Concentration Ratios (CR8) for Antibody-drug Conjugates in 2025
3.3 Antibody-drug Conjugates Company Evaluation Quadrant
3.4 Antibody-drug Conjugates Market: Overall Company Footprint Analysis
3.4.1 Antibody-drug Conjugates Market: Region Footprint
3.4.2 Antibody-drug Conjugates Market: Company Product Type Footprint
3.4.3 Antibody-drug Conjugates Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Antibody-drug Conjugates Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Antibody-drug Conjugates Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Antibody-drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Antibody-drug Conjugates Consumption Value Comparison
4.2.1 United States VS China: Antibody-drug Conjugates Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Antibody-drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Antibody-drug Conjugates Companies and Market Share, 2021-2026
4.3.1 United States Based Antibody-drug Conjugates Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Antibody-drug Conjugates Revenue, (2021-2026)
4.4 China Based Companies Antibody-drug Conjugates Revenue and Market Share, 2021-2026
4.4.1 China Based Antibody-drug Conjugates Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Antibody-drug Conjugates Revenue, (2021-2026)
4.5 Rest of World Based Antibody-drug Conjugates Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Antibody-drug Conjugates Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Antibody-drug Conjugates Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Antibody-drug Conjugates Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 HER2-Directed ADCs
5.2.2 TROP2-Directed ADCs
5.2.3 Hematologic-Lineage Antigen ADCs
5.2.4 Other Target Antigen ADCs
5.3 Market Segment by Type
5.3.1 World Antibody-drug Conjugates Market Size by Type (2021-2026)
5.3.2 World Antibody-drug Conjugates Market Size by Type (2027-2032)
5.3.3 World Antibody-drug Conjugates Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY PAYLOAD MECHANISM
6.1 World Antibody-drug Conjugates Market Size Overview by Payload Mechanism: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Payload Mechanism
6.2.1 Topoisomerase I Inhibitor ADCs
6.2.2 Microtubule Inhibitor ADCs
6.2.3 DNA-Damaging ADCs
6.2.4 Other Payload ADCs
6.3 Market Segment by Payload Mechanism
6.3.1 World Antibody-drug Conjugates Market Size by Payload Mechanism (2021-2026)
6.3.2 World Antibody-drug Conjugates Market Size by Payload Mechanism (2027-2032)
6.3.3 World Antibody-drug Conjugates Market Size Market Share by Payload Mechanism (2027-2032)
7 MARKET ANALYSIS BY DRUG-TO-ANTIBODY RATIO
7.1 World Antibody-drug Conjugates Market Size Overview by Drug-To-Antibody Ratio: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Drug-To-Antibody Ratio
7.2.1 DAR Up To 4
7.2.2 DAR Above 4 And Below 8
7.2.3 DAR 8 And Above
7.2.4 Other
7.3 Market Segment by Drug-To-Antibody Ratio
7.3.1 World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio (2021-2026)
7.3.2 World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio (2027-2032)
7.3.3 World Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Antibody-drug Conjugates Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Breast and Gynecologic Malignancies
8.2.2 Lung and Other Thoracic Malignancies
8.2.3 Other Solid Tumors
8.2.4 Hematologic Malignancies
8.3 Market Segment by Application
8.3.1 World Antibody-drug Conjugates Market Size by Application (2021-2026)
8.3.2 World Antibody-drug Conjugates Market Size by Application (2027-2032)
8.3.3 World Antibody-drug Conjugates Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Daiichi Sankyo Company, Limited
9.1.1 Daiichi Sankyo Company, Limited Details
9.1.2 Daiichi Sankyo Company, Limited Major Business
9.1.3 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Services
9.1.4 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
9.1.6 Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Antibody-drug Conjugates Product and Services
9.2.4 Roche Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 Pfizer Inc.
9.3.1 Pfizer Inc. Details
9.3.2 Pfizer Inc. Major Business
9.3.3 Pfizer Inc. Antibody-drug Conjugates Product and Services
9.3.4 Pfizer Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Pfizer Inc. Recent Developments/Updates
9.3.6 Pfizer Inc. Competitive Strengths & Weaknesses
9.4 Gilead Sciences, Inc.
9.4.1 Gilead Sciences, Inc. Details
9.4.2 Gilead Sciences, Inc. Major Business
9.4.3 Gilead Sciences, Inc. Antibody-drug Conjugates Product and Services
9.4.4 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Gilead Sciences, Inc. Recent Developments/Updates
9.4.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
9.5 Astellas Pharma Inc.
9.5.1 Astellas Pharma Inc. Details
9.5.2 Astellas Pharma Inc. Major Business
9.5.3 Astellas Pharma Inc. Antibody-drug Conjugates Product and Services
9.5.4 Astellas Pharma Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Astellas Pharma Inc. Recent Developments/Updates
9.5.6 Astellas Pharma Inc. Competitive Strengths & Weaknesses
9.6 AbbVie Inc.
9.6.1 AbbVie Inc. Details
9.6.2 AbbVie Inc. Major Business
9.6.3 AbbVie Inc. Antibody-drug Conjugates Product and Services
9.6.4 AbbVie Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 AbbVie Inc. Recent Developments/Updates
9.6.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.7 GSK plc
9.7.1 GSK plc Details
9.7.2 GSK plc Major Business
9.7.3 GSK plc Antibody-drug Conjugates Product and Services
9.7.4 GSK plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 GSK plc Recent Developments/Updates
9.7.6 GSK plc Competitive Strengths & Weaknesses
9.8 ADC Therapeutics SA
9.8.1 ADC Therapeutics SA Details
9.8.2 ADC Therapeutics SA Major Business
9.8.3 ADC Therapeutics SA Antibody-drug Conjugates Product and Services
9.8.4 ADC Therapeutics SA Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 ADC Therapeutics SA Recent Developments/Updates
9.8.6 ADC Therapeutics SA Competitive Strengths & Weaknesses
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Takeda Pharmaceutical Company Limited Details
9.9.2 Takeda Pharmaceutical Company Limited Major Business
9.9.3 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Services
9.9.4 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
9.9.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
9.10 AstraZeneca plc
9.10.1 AstraZeneca plc Details
9.10.2 AstraZeneca plc Major Business
9.10.3 AstraZeneca plc Antibody-drug Conjugates Product and Services
9.10.4 AstraZeneca plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 AstraZeneca plc Recent Developments/Updates
9.10.6 AstraZeneca plc Competitive Strengths & Weaknesses
9.11 Genmab A/S
9.11.1 Genmab A/S Details
9.11.2 Genmab A/S Major Business
9.11.3 Genmab A/S Antibody-drug Conjugates Product and Services
9.11.4 Genmab A/S Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Genmab A/S Recent Developments/Updates
9.11.6 Genmab A/S Competitive Strengths & Weaknesses
9.12 Johnson & Johnson
9.12.1 Johnson & Johnson Details
9.12.2 Johnson & Johnson Major Business
9.12.3 Johnson & Johnson Antibody-drug Conjugates Product and Services
9.12.4 Johnson & Johnson Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Johnson & Johnson Recent Developments/Updates
9.12.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.13 Merck & Co., Inc.
9.13.1 Merck & Co., Inc. Details
9.13.2 Merck & Co., Inc. Major Business
9.13.3 Merck & Co., Inc. Antibody-drug Conjugates Product and Services
9.13.4 Merck & Co., Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Merck & Co., Inc. Recent Developments/Updates
9.13.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
9.14 MacroGenics, Inc.
9.14.1 MacroGenics, Inc. Details
9.14.2 MacroGenics, Inc. Major Business
9.14.3 MacroGenics, Inc. Antibody-drug Conjugates Product and Services
9.14.4 MacroGenics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 MacroGenics, Inc. Recent Developments/Updates
9.14.6 MacroGenics, Inc. Competitive Strengths & Weaknesses
9.15 Sutro Biopharma, Inc.
9.15.1 Sutro Biopharma, Inc. Details
9.15.2 Sutro Biopharma, Inc. Major Business
9.15.3 Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Services
9.15.4 Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Sutro Biopharma, Inc. Recent Developments/Updates
9.15.6 Sutro Biopharma, Inc. Competitive Strengths & Weaknesses
9.16 Heidelberg Pharma AG
9.16.1 Heidelberg Pharma AG Details
9.16.2 Heidelberg Pharma AG Major Business
9.16.3 Heidelberg Pharma AG Antibody-drug Conjugates Product and Services
9.16.4 Heidelberg Pharma AG Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Heidelberg Pharma AG Recent Developments/Updates
9.16.6 Heidelberg Pharma AG Competitive Strengths & Weaknesses
9.17 RemeGen Co., Ltd.
9.17.1 RemeGen Co., Ltd. Details
9.17.2 RemeGen Co., Ltd. Major Business
9.17.3 RemeGen Co., Ltd. Antibody-drug Conjugates Product and Services
9.17.4 RemeGen Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 RemeGen Co., Ltd. Recent Developments/Updates
9.17.6 RemeGen Co., Ltd. Competitive Strengths & Weaknesses
9.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
9.18.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details
9.18.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
9.18.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
9.18.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
9.18.6 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.19 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
9.19.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
9.19.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
9.19.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Services
9.19.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
9.19.6 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
9.20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
9.20.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Details
9.20.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
9.20.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Services
9.20.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments/Updates
9.20.6 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Competitive Strengths & Weaknesses
9.21 Innovent Biologics, Inc.
9.21.1 Innovent Biologics, Inc. Details
9.21.2 Innovent Biologics, Inc. Major Business
9.21.3 Innovent Biologics, Inc. Antibody-drug Conjugates Product and Services
9.21.4 Innovent Biologics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Innovent Biologics, Inc. Recent Developments/Updates
9.21.6 Innovent Biologics, Inc. Competitive Strengths & Weaknesses
9.22 CSPC Pharmaceutical Group Limited
9.22.1 CSPC Pharmaceutical Group Limited Details
9.22.2 CSPC Pharmaceutical Group Limited Major Business
9.22.3 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Services
9.22.4 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 CSPC Pharmaceutical Group Limited Recent Developments/Updates
9.22.6 CSPC Pharmaceutical Group Limited Competitive Strengths & Weaknesses
9.23 Mabwell (Shanghai) Bioscience Co., Ltd.
9.23.1 Mabwell (Shanghai) Bioscience Co., Ltd. Details
9.23.2 Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
9.23.3 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Services
9.23.4 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments/Updates
9.23.6 Mabwell (Shanghai) Bioscience Co., Ltd. Competitive Strengths & Weaknesses
9.24 Lepu Biopharma Co., Ltd.
9.24.1 Lepu Biopharma Co., Ltd. Details
9.24.2 Lepu Biopharma Co., Ltd. Major Business
9.24.3 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Services
9.24.4 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Lepu Biopharma Co., Ltd. Recent Developments/Updates
9.24.6 Lepu Biopharma Co., Ltd. Competitive Strengths & Weaknesses
9.25 Duality Biologics (Shanghai) Co., Ltd.
9.25.1 Duality Biologics (Shanghai) Co., Ltd. Details
9.25.2 Duality Biologics (Shanghai) Co., Ltd. Major Business
9.25.3 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Services
9.25.4 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Duality Biologics (Shanghai) Co., Ltd. Recent Developments/Updates
9.25.6 Duality Biologics (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
9.26 MediLink Therapeutics (Suzhou) Co., Ltd.
9.26.1 MediLink Therapeutics (Suzhou) Co., Ltd. Details
9.26.2 MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
9.26.3 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
9.26.4 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments/Updates
9.26.6 MediLink Therapeutics (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
9.27 GeneQuantum Healthcare (Suzhou) Co., Ltd.
9.27.1 GeneQuantum Healthcare (Suzhou) Co., Ltd. Details
9.27.2 GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
9.27.3 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
9.27.4 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.27.5 GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments/Updates
9.27.6 GeneQuantum Healthcare (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
9.28 Hangzhou DAC Biotechnology Co., Ltd.
9.28.1 Hangzhou DAC Biotechnology Co., Ltd. Details
9.28.2 Hangzhou DAC Biotechnology Co., Ltd. Major Business
9.28.3 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Services
9.28.4 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.28.5 Hangzhou DAC Biotechnology Co., Ltd. Recent Developments/Updates
9.28.6 Hangzhou DAC Biotechnology Co., Ltd. Competitive Strengths & Weaknesses
9.29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
9.29.1 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Details
9.29.2 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
9.29.3 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
9.29.4 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.29.5 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments/Updates
9.29.6 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Competitive Strengths & Weaknesses
9.30 Sichuan Biokin Pharmaceutical Co., Ltd.
9.30.1 Sichuan Biokin Pharmaceutical Co., Ltd. Details
9.30.2 Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
9.30.3 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
9.30.4 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.30.5 Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments/Updates
9.30.6 Sichuan Biokin Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.31 Bio-Thera Solutions, Ltd.
9.31.1 Bio-Thera Solutions, Ltd. Details
9.31.2 Bio-Thera Solutions, Ltd. Major Business
9.31.3 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Services
9.31.4 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.31.5 Bio-Thera Solutions, Ltd. Recent Developments/Updates
9.31.6 Bio-Thera Solutions, Ltd. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Antibody-drug Conjugates Industry Chain
10.2 Antibody-drug Conjugates Upstream Analysis
10.3 Antibody-drug Conjugates Midstream Analysis
10.4 Antibody-drug Conjugates Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Antibody-drug Conjugates Introduction
1.2 World Antibody-drug Conjugates Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Antibody-drug Conjugates Total Market by Region (by Headquarter Location)
1.3.1 World Antibody-drug Conjugates Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.3 China Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.4 Europe Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.5 Japan Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.6 South Korea Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.7 ASEAN Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.3.8 India Based Company Antibody-drug Conjugates Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Antibody-drug Conjugates Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Antibody-drug Conjugates Consumption Value (2021-2032)
2.2 World Antibody-drug Conjugates Consumption Value by Region
2.2.1 World Antibody-drug Conjugates Consumption Value by Region (2021-2026)
2.2.2 World Antibody-drug Conjugates Consumption Value Forecast by Region (2027-2032)
2.3 United States Antibody-drug Conjugates Consumption Value (2021-2032)
2.4 China Antibody-drug Conjugates Consumption Value (2021-2032)
2.5 Europe Antibody-drug Conjugates Consumption Value (2021-2032)
2.6 Japan Antibody-drug Conjugates Consumption Value (2021-2032)
2.7 South Korea Antibody-drug Conjugates Consumption Value (2021-2032)
2.8 ASEAN Antibody-drug Conjugates Consumption Value (2021-2032)
2.9 India Antibody-drug Conjugates Consumption Value (2021-2032)
3 WORLD ANTIBODY-DRUG CONJUGATES COMPANIES COMPETITIVE ANALYSIS
3.1 World Antibody-drug Conjugates Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Antibody-drug Conjugates Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Antibody-drug Conjugates in 2025
3.2.3 Global Concentration Ratios (CR8) for Antibody-drug Conjugates in 2025
3.3 Antibody-drug Conjugates Company Evaluation Quadrant
3.4 Antibody-drug Conjugates Market: Overall Company Footprint Analysis
3.4.1 Antibody-drug Conjugates Market: Region Footprint
3.4.2 Antibody-drug Conjugates Market: Company Product Type Footprint
3.4.3 Antibody-drug Conjugates Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Antibody-drug Conjugates Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Antibody-drug Conjugates Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Antibody-drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Antibody-drug Conjugates Consumption Value Comparison
4.2.1 United States VS China: Antibody-drug Conjugates Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Antibody-drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Antibody-drug Conjugates Companies and Market Share, 2021-2026
4.3.1 United States Based Antibody-drug Conjugates Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Antibody-drug Conjugates Revenue, (2021-2026)
4.4 China Based Companies Antibody-drug Conjugates Revenue and Market Share, 2021-2026
4.4.1 China Based Antibody-drug Conjugates Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Antibody-drug Conjugates Revenue, (2021-2026)
4.5 Rest of World Based Antibody-drug Conjugates Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Antibody-drug Conjugates Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Antibody-drug Conjugates Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Antibody-drug Conjugates Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 HER2-Directed ADCs
5.2.2 TROP2-Directed ADCs
5.2.3 Hematologic-Lineage Antigen ADCs
5.2.4 Other Target Antigen ADCs
5.3 Market Segment by Type
5.3.1 World Antibody-drug Conjugates Market Size by Type (2021-2026)
5.3.2 World Antibody-drug Conjugates Market Size by Type (2027-2032)
5.3.3 World Antibody-drug Conjugates Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY PAYLOAD MECHANISM
6.1 World Antibody-drug Conjugates Market Size Overview by Payload Mechanism: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Payload Mechanism
6.2.1 Topoisomerase I Inhibitor ADCs
6.2.2 Microtubule Inhibitor ADCs
6.2.3 DNA-Damaging ADCs
6.2.4 Other Payload ADCs
6.3 Market Segment by Payload Mechanism
6.3.1 World Antibody-drug Conjugates Market Size by Payload Mechanism (2021-2026)
6.3.2 World Antibody-drug Conjugates Market Size by Payload Mechanism (2027-2032)
6.3.3 World Antibody-drug Conjugates Market Size Market Share by Payload Mechanism (2027-2032)
7 MARKET ANALYSIS BY DRUG-TO-ANTIBODY RATIO
7.1 World Antibody-drug Conjugates Market Size Overview by Drug-To-Antibody Ratio: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Drug-To-Antibody Ratio
7.2.1 DAR Up To 4
7.2.2 DAR Above 4 And Below 8
7.2.3 DAR 8 And Above
7.2.4 Other
7.3 Market Segment by Drug-To-Antibody Ratio
7.3.1 World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio (2021-2026)
7.3.2 World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio (2027-2032)
7.3.3 World Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Antibody-drug Conjugates Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Breast and Gynecologic Malignancies
8.2.2 Lung and Other Thoracic Malignancies
8.2.3 Other Solid Tumors
8.2.4 Hematologic Malignancies
8.3 Market Segment by Application
8.3.1 World Antibody-drug Conjugates Market Size by Application (2021-2026)
8.3.2 World Antibody-drug Conjugates Market Size by Application (2027-2032)
8.3.3 World Antibody-drug Conjugates Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 Daiichi Sankyo Company, Limited
9.1.1 Daiichi Sankyo Company, Limited Details
9.1.2 Daiichi Sankyo Company, Limited Major Business
9.1.3 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Services
9.1.4 Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Daiichi Sankyo Company, Limited Recent Developments/Updates
9.1.6 Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
9.2 Roche
9.2.1 Roche Details
9.2.2 Roche Major Business
9.2.3 Roche Antibody-drug Conjugates Product and Services
9.2.4 Roche Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Roche Recent Developments/Updates
9.2.6 Roche Competitive Strengths & Weaknesses
9.3 Pfizer Inc.
9.3.1 Pfizer Inc. Details
9.3.2 Pfizer Inc. Major Business
9.3.3 Pfizer Inc. Antibody-drug Conjugates Product and Services
9.3.4 Pfizer Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Pfizer Inc. Recent Developments/Updates
9.3.6 Pfizer Inc. Competitive Strengths & Weaknesses
9.4 Gilead Sciences, Inc.
9.4.1 Gilead Sciences, Inc. Details
9.4.2 Gilead Sciences, Inc. Major Business
9.4.3 Gilead Sciences, Inc. Antibody-drug Conjugates Product and Services
9.4.4 Gilead Sciences, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Gilead Sciences, Inc. Recent Developments/Updates
9.4.6 Gilead Sciences, Inc. Competitive Strengths & Weaknesses
9.5 Astellas Pharma Inc.
9.5.1 Astellas Pharma Inc. Details
9.5.2 Astellas Pharma Inc. Major Business
9.5.3 Astellas Pharma Inc. Antibody-drug Conjugates Product and Services
9.5.4 Astellas Pharma Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Astellas Pharma Inc. Recent Developments/Updates
9.5.6 Astellas Pharma Inc. Competitive Strengths & Weaknesses
9.6 AbbVie Inc.
9.6.1 AbbVie Inc. Details
9.6.2 AbbVie Inc. Major Business
9.6.3 AbbVie Inc. Antibody-drug Conjugates Product and Services
9.6.4 AbbVie Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 AbbVie Inc. Recent Developments/Updates
9.6.6 AbbVie Inc. Competitive Strengths & Weaknesses
9.7 GSK plc
9.7.1 GSK plc Details
9.7.2 GSK plc Major Business
9.7.3 GSK plc Antibody-drug Conjugates Product and Services
9.7.4 GSK plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 GSK plc Recent Developments/Updates
9.7.6 GSK plc Competitive Strengths & Weaknesses
9.8 ADC Therapeutics SA
9.8.1 ADC Therapeutics SA Details
9.8.2 ADC Therapeutics SA Major Business
9.8.3 ADC Therapeutics SA Antibody-drug Conjugates Product and Services
9.8.4 ADC Therapeutics SA Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 ADC Therapeutics SA Recent Developments/Updates
9.8.6 ADC Therapeutics SA Competitive Strengths & Weaknesses
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Takeda Pharmaceutical Company Limited Details
9.9.2 Takeda Pharmaceutical Company Limited Major Business
9.9.3 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Services
9.9.4 Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
9.9.6 Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
9.10 AstraZeneca plc
9.10.1 AstraZeneca plc Details
9.10.2 AstraZeneca plc Major Business
9.10.3 AstraZeneca plc Antibody-drug Conjugates Product and Services
9.10.4 AstraZeneca plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 AstraZeneca plc Recent Developments/Updates
9.10.6 AstraZeneca plc Competitive Strengths & Weaknesses
9.11 Genmab A/S
9.11.1 Genmab A/S Details
9.11.2 Genmab A/S Major Business
9.11.3 Genmab A/S Antibody-drug Conjugates Product and Services
9.11.4 Genmab A/S Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Genmab A/S Recent Developments/Updates
9.11.6 Genmab A/S Competitive Strengths & Weaknesses
9.12 Johnson & Johnson
9.12.1 Johnson & Johnson Details
9.12.2 Johnson & Johnson Major Business
9.12.3 Johnson & Johnson Antibody-drug Conjugates Product and Services
9.12.4 Johnson & Johnson Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Johnson & Johnson Recent Developments/Updates
9.12.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.13 Merck & Co., Inc.
9.13.1 Merck & Co., Inc. Details
9.13.2 Merck & Co., Inc. Major Business
9.13.3 Merck & Co., Inc. Antibody-drug Conjugates Product and Services
9.13.4 Merck & Co., Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Merck & Co., Inc. Recent Developments/Updates
9.13.6 Merck & Co., Inc. Competitive Strengths & Weaknesses
9.14 MacroGenics, Inc.
9.14.1 MacroGenics, Inc. Details
9.14.2 MacroGenics, Inc. Major Business
9.14.3 MacroGenics, Inc. Antibody-drug Conjugates Product and Services
9.14.4 MacroGenics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 MacroGenics, Inc. Recent Developments/Updates
9.14.6 MacroGenics, Inc. Competitive Strengths & Weaknesses
9.15 Sutro Biopharma, Inc.
9.15.1 Sutro Biopharma, Inc. Details
9.15.2 Sutro Biopharma, Inc. Major Business
9.15.3 Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Services
9.15.4 Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Sutro Biopharma, Inc. Recent Developments/Updates
9.15.6 Sutro Biopharma, Inc. Competitive Strengths & Weaknesses
9.16 Heidelberg Pharma AG
9.16.1 Heidelberg Pharma AG Details
9.16.2 Heidelberg Pharma AG Major Business
9.16.3 Heidelberg Pharma AG Antibody-drug Conjugates Product and Services
9.16.4 Heidelberg Pharma AG Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 Heidelberg Pharma AG Recent Developments/Updates
9.16.6 Heidelberg Pharma AG Competitive Strengths & Weaknesses
9.17 RemeGen Co., Ltd.
9.17.1 RemeGen Co., Ltd. Details
9.17.2 RemeGen Co., Ltd. Major Business
9.17.3 RemeGen Co., Ltd. Antibody-drug Conjugates Product and Services
9.17.4 RemeGen Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 RemeGen Co., Ltd. Recent Developments/Updates
9.17.6 RemeGen Co., Ltd. Competitive Strengths & Weaknesses
9.18 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
9.18.1 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Details
9.18.2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
9.18.3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
9.18.4 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
9.18.6 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.19 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
9.19.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Details
9.19.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
9.19.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Services
9.19.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
9.19.6 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
9.20 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
9.20.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Details
9.20.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
9.20.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Services
9.20.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments/Updates
9.20.6 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Competitive Strengths & Weaknesses
9.21 Innovent Biologics, Inc.
9.21.1 Innovent Biologics, Inc. Details
9.21.2 Innovent Biologics, Inc. Major Business
9.21.3 Innovent Biologics, Inc. Antibody-drug Conjugates Product and Services
9.21.4 Innovent Biologics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Innovent Biologics, Inc. Recent Developments/Updates
9.21.6 Innovent Biologics, Inc. Competitive Strengths & Weaknesses
9.22 CSPC Pharmaceutical Group Limited
9.22.1 CSPC Pharmaceutical Group Limited Details
9.22.2 CSPC Pharmaceutical Group Limited Major Business
9.22.3 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Services
9.22.4 CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 CSPC Pharmaceutical Group Limited Recent Developments/Updates
9.22.6 CSPC Pharmaceutical Group Limited Competitive Strengths & Weaknesses
9.23 Mabwell (Shanghai) Bioscience Co., Ltd.
9.23.1 Mabwell (Shanghai) Bioscience Co., Ltd. Details
9.23.2 Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
9.23.3 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Services
9.23.4 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments/Updates
9.23.6 Mabwell (Shanghai) Bioscience Co., Ltd. Competitive Strengths & Weaknesses
9.24 Lepu Biopharma Co., Ltd.
9.24.1 Lepu Biopharma Co., Ltd. Details
9.24.2 Lepu Biopharma Co., Ltd. Major Business
9.24.3 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Services
9.24.4 Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Lepu Biopharma Co., Ltd. Recent Developments/Updates
9.24.6 Lepu Biopharma Co., Ltd. Competitive Strengths & Weaknesses
9.25 Duality Biologics (Shanghai) Co., Ltd.
9.25.1 Duality Biologics (Shanghai) Co., Ltd. Details
9.25.2 Duality Biologics (Shanghai) Co., Ltd. Major Business
9.25.3 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Services
9.25.4 Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Duality Biologics (Shanghai) Co., Ltd. Recent Developments/Updates
9.25.6 Duality Biologics (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
9.26 MediLink Therapeutics (Suzhou) Co., Ltd.
9.26.1 MediLink Therapeutics (Suzhou) Co., Ltd. Details
9.26.2 MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
9.26.3 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
9.26.4 MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.26.5 MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments/Updates
9.26.6 MediLink Therapeutics (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
9.27 GeneQuantum Healthcare (Suzhou) Co., Ltd.
9.27.1 GeneQuantum Healthcare (Suzhou) Co., Ltd. Details
9.27.2 GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
9.27.3 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
9.27.4 GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.27.5 GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments/Updates
9.27.6 GeneQuantum Healthcare (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
9.28 Hangzhou DAC Biotechnology Co., Ltd.
9.28.1 Hangzhou DAC Biotechnology Co., Ltd. Details
9.28.2 Hangzhou DAC Biotechnology Co., Ltd. Major Business
9.28.3 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Services
9.28.4 Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.28.5 Hangzhou DAC Biotechnology Co., Ltd. Recent Developments/Updates
9.28.6 Hangzhou DAC Biotechnology Co., Ltd. Competitive Strengths & Weaknesses
9.29 Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
9.29.1 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Details
9.29.2 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
9.29.3 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
9.29.4 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.29.5 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments/Updates
9.29.6 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Competitive Strengths & Weaknesses
9.30 Sichuan Biokin Pharmaceutical Co., Ltd.
9.30.1 Sichuan Biokin Pharmaceutical Co., Ltd. Details
9.30.2 Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
9.30.3 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
9.30.4 Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.30.5 Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments/Updates
9.30.6 Sichuan Biokin Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
9.31 Bio-Thera Solutions, Ltd.
9.31.1 Bio-Thera Solutions, Ltd. Details
9.31.2 Bio-Thera Solutions, Ltd. Major Business
9.31.3 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Services
9.31.4 Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026)
9.31.5 Bio-Thera Solutions, Ltd. Recent Developments/Updates
9.31.6 Bio-Thera Solutions, Ltd. Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Antibody-drug Conjugates Industry Chain
10.2 Antibody-drug Conjugates Upstream Analysis
10.3 Antibody-drug Conjugates Midstream Analysis
10.4 Antibody-drug Conjugates Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Antibody-drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Antibody-drug Conjugates Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Antibody-drug Conjugates Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Antibody-drug Conjugates Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Antibody-drug Conjugates Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Antibody-drug Conjugates Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Antibody-drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Antibody-drug Conjugates Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Antibody-drug Conjugates Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Antibody-drug Conjugates Players in 2025
Table 12. World Antibody-drug Conjugates Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Antibody-drug Conjugates Company Evaluation Quadrant
Table 14. Head Office of Key Antibody-drug Conjugates Players
Table 15. Antibody-drug Conjugates Market: Company Product Type Footprint
Table 16. Antibody-drug Conjugates Market: Company Product Application Footprint
Table 17. Antibody-drug Conjugates Mergers & Acquisitions Activity
Table 18. United States VS China Antibody-drug Conjugates Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Antibody-drug Conjugates Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Antibody-drug Conjugates Companies, Headquarters (States, Country)
Table 21. United States Based Companies Antibody-drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Antibody-drug Conjugates Revenue Market Share (2021-2026)
Table 23. China Based Antibody-drug Conjugates Companies, Headquarters (Province, Country)
Table 24. China Based Companies Antibody-drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Antibody-drug Conjugates Revenue Market Share (2021-2026)
Table 26. Rest of World Based Antibody-drug Conjugates Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Antibody-drug Conjugates Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Antibody-drug Conjugates Revenue Market Share (2021-2026)
Table 29. World Antibody-drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Antibody-drug Conjugates Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Antibody-drug Conjugates Market Size by Type (2027-2032) & (USD Million)
Table 32. World Antibody-drug Conjugates Market Size by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Table 33. World Antibody-drug Conjugates Market Size Value by Payload Mechanism (2021-2026) & (USD Million)
Table 34. World Antibody-drug Conjugates Market Size by Payload Mechanism (2027-2032) & (USD Million)
Table 35. World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Table 36. World Antibody-drug Conjugates Market Size Value by Drug-To-Antibody Ratio (2021-2026) & (USD Million)
Table 37. World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio (2027-2032) & (USD Million)
Table 38. World Antibody-drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Antibody-drug Conjugates Market Size by Application (2021-2026) & (USD Million)
Table 40. World Antibody-drug Conjugates Market Size by Application (2027-2032) & (USD Million)
Table 41. Daiichi Sankyo Company, Limited Basic Information, Manufacturing Base and Competitors
Table 42. Daiichi Sankyo Company, Limited Major Business
Table 43. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Services
Table 44. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Daiichi Sankyo Company, Limited Recent Developments/Updates
Table 46. Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Antibody-drug Conjugates Product and Services
Table 50. Roche Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Pfizer Inc. Major Business
Table 55. Pfizer Inc. Antibody-drug Conjugates Product and Services
Table 56. Pfizer Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Pfizer Inc. Recent Developments/Updates
Table 58. Pfizer Inc. Competitive Strengths & Weaknesses
Table 59. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 60. Gilead Sciences, Inc. Major Business
Table 61. Gilead Sciences, Inc. Antibody-drug Conjugates Product and Services
Table 62. Gilead Sciences, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Gilead Sciences, Inc. Recent Developments/Updates
Table 64. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 65. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 66. Astellas Pharma Inc. Major Business
Table 67. Astellas Pharma Inc. Antibody-drug Conjugates Product and Services
Table 68. Astellas Pharma Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Astellas Pharma Inc. Recent Developments/Updates
Table 70. Astellas Pharma Inc. Competitive Strengths & Weaknesses
Table 71. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 72. AbbVie Inc. Major Business
Table 73. AbbVie Inc. Antibody-drug Conjugates Product and Services
Table 74. AbbVie Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. AbbVie Inc. Recent Developments/Updates
Table 76. AbbVie Inc. Competitive Strengths & Weaknesses
Table 77. GSK plc Basic Information, Manufacturing Base and Competitors
Table 78. GSK plc Major Business
Table 79. GSK plc Antibody-drug Conjugates Product and Services
Table 80. GSK plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. GSK plc Recent Developments/Updates
Table 82. GSK plc Competitive Strengths & Weaknesses
Table 83. ADC Therapeutics SA Basic Information, Manufacturing Base and Competitors
Table 84. ADC Therapeutics SA Major Business
Table 85. ADC Therapeutics SA Antibody-drug Conjugates Product and Services
Table 86. ADC Therapeutics SA Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. ADC Therapeutics SA Recent Developments/Updates
Table 88. ADC Therapeutics SA Competitive Strengths & Weaknesses
Table 89. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 90. Takeda Pharmaceutical Company Limited Major Business
Table 91. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Services
Table 92. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 94. Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
Table 95. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 96. AstraZeneca plc Major Business
Table 97. AstraZeneca plc Antibody-drug Conjugates Product and Services
Table 98. AstraZeneca plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. AstraZeneca plc Recent Developments/Updates
Table 100. AstraZeneca plc Competitive Strengths & Weaknesses
Table 101. Genmab A/S Basic Information, Manufacturing Base and Competitors
Table 102. Genmab A/S Major Business
Table 103. Genmab A/S Antibody-drug Conjugates Product and Services
Table 104. Genmab A/S Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Genmab A/S Recent Developments/Updates
Table 106. Genmab A/S Competitive Strengths & Weaknesses
Table 107. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 108. Johnson & Johnson Major Business
Table 109. Johnson & Johnson Antibody-drug Conjugates Product and Services
Table 110. Johnson & Johnson Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Johnson & Johnson Recent Developments/Updates
Table 112. Johnson & Johnson Competitive Strengths & Weaknesses
Table 113. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 114. Merck & Co., Inc. Major Business
Table 115. Merck & Co., Inc. Antibody-drug Conjugates Product and Services
Table 116. Merck & Co., Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Merck & Co., Inc. Recent Developments/Updates
Table 118. Merck & Co., Inc. Competitive Strengths & Weaknesses
Table 119. MacroGenics, Inc. Basic Information, Manufacturing Base and Competitors
Table 120. MacroGenics, Inc. Major Business
Table 121. MacroGenics, Inc. Antibody-drug Conjugates Product and Services
Table 122. MacroGenics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. MacroGenics, Inc. Recent Developments/Updates
Table 124. MacroGenics, Inc. Competitive Strengths & Weaknesses
Table 125. Sutro Biopharma, Inc. Basic Information, Manufacturing Base and Competitors
Table 126. Sutro Biopharma, Inc. Major Business
Table 127. Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Services
Table 128. Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Sutro Biopharma, Inc. Recent Developments/Updates
Table 130. Sutro Biopharma, Inc. Competitive Strengths & Weaknesses
Table 131. Heidelberg Pharma AG Basic Information, Manufacturing Base and Competitors
Table 132. Heidelberg Pharma AG Major Business
Table 133. Heidelberg Pharma AG Antibody-drug Conjugates Product and Services
Table 134. Heidelberg Pharma AG Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Heidelberg Pharma AG Recent Developments/Updates
Table 136. Heidelberg Pharma AG Competitive Strengths & Weaknesses
Table 137. RemeGen Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 138. RemeGen Co., Ltd. Major Business
Table 139. RemeGen Co., Ltd. Antibody-drug Conjugates Product and Services
Table 140. RemeGen Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. RemeGen Co., Ltd. Recent Developments/Updates
Table 142. RemeGen Co., Ltd. Competitive Strengths & Weaknesses
Table 143. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 144. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
Table 145. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
Table 146. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
Table 148. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 149. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 150. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
Table 151. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Services
Table 152. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
Table 154. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
Table 155. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 156. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
Table 157. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Services
Table 158. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments/Updates
Table 160. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Competitive Strengths & Weaknesses
Table 161. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 162. Innovent Biologics, Inc. Major Business
Table 163. Innovent Biologics, Inc. Antibody-drug Conjugates Product and Services
Table 164. Innovent Biologics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Innovent Biologics, Inc. Recent Developments/Updates
Table 166. Innovent Biologics, Inc. Competitive Strengths & Weaknesses
Table 167. CSPC Pharmaceutical Group Limited Basic Information, Manufacturing Base and Competitors
Table 168. CSPC Pharmaceutical Group Limited Major Business
Table 169. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Services
Table 170. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. CSPC Pharmaceutical Group Limited Recent Developments/Updates
Table 172. CSPC Pharmaceutical Group Limited Competitive Strengths & Weaknesses
Table 173. Mabwell (Shanghai) Bioscience Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 174. Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
Table 175. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Services
Table 176. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments/Updates
Table 178. Mabwell (Shanghai) Bioscience Co., Ltd. Competitive Strengths & Weaknesses
Table 179. Lepu Biopharma Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 180. Lepu Biopharma Co., Ltd. Major Business
Table 181. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Services
Table 182. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Lepu Biopharma Co., Ltd. Recent Developments/Updates
Table 184. Lepu Biopharma Co., Ltd. Competitive Strengths & Weaknesses
Table 185. Duality Biologics (Shanghai) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 186. Duality Biologics (Shanghai) Co., Ltd. Major Business
Table 187. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 188. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Duality Biologics (Shanghai) Co., Ltd. Recent Developments/Updates
Table 190. Duality Biologics (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
Table 191. MediLink Therapeutics (Suzhou) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 192. MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
Table 193. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 194. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments/Updates
Table 196. MediLink Therapeutics (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
Table 197. GeneQuantum Healthcare (Suzhou) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 198. GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
Table 199. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 200. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 201. GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments/Updates
Table 202. GeneQuantum Healthcare (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
Table 203. Hangzhou DAC Biotechnology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 204. Hangzhou DAC Biotechnology Co., Ltd. Major Business
Table 205. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Services
Table 206. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 207. Hangzhou DAC Biotechnology Co., Ltd. Recent Developments/Updates
Table 208. Hangzhou DAC Biotechnology Co., Ltd. Competitive Strengths & Weaknesses
Table 209. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 210. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
Table 211. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 212. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 213. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments/Updates
Table 214. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Competitive Strengths & Weaknesses
Table 215. Sichuan Biokin Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 216. Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
Table 217. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
Table 218. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 219. Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 220. Sichuan Biokin Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 221. Bio-Thera Solutions, Ltd. Basic Information, Manufacturing Base and Competitors
Table 222. Bio-Thera Solutions, Ltd. Major Business
Table 223. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Services
Table 224. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 225. Bio-Thera Solutions, Ltd. Recent Developments/Updates
Table 226. Bio-Thera Solutions, Ltd. Competitive Strengths & Weaknesses
Table 227. Global Key Players of Antibody-drug Conjugates Upstream (Raw Materials)
Table 228. Global Antibody-drug Conjugates Typical Customers
Table 1. World Antibody-drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Antibody-drug Conjugates Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Antibody-drug Conjugates Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Antibody-drug Conjugates Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Antibody-drug Conjugates Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Antibody-drug Conjugates Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Antibody-drug Conjugates Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Antibody-drug Conjugates Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Antibody-drug Conjugates Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Antibody-drug Conjugates Players in 2025
Table 12. World Antibody-drug Conjugates Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Antibody-drug Conjugates Company Evaluation Quadrant
Table 14. Head Office of Key Antibody-drug Conjugates Players
Table 15. Antibody-drug Conjugates Market: Company Product Type Footprint
Table 16. Antibody-drug Conjugates Market: Company Product Application Footprint
Table 17. Antibody-drug Conjugates Mergers & Acquisitions Activity
Table 18. United States VS China Antibody-drug Conjugates Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Antibody-drug Conjugates Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Antibody-drug Conjugates Companies, Headquarters (States, Country)
Table 21. United States Based Companies Antibody-drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Antibody-drug Conjugates Revenue Market Share (2021-2026)
Table 23. China Based Antibody-drug Conjugates Companies, Headquarters (Province, Country)
Table 24. China Based Companies Antibody-drug Conjugates Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Antibody-drug Conjugates Revenue Market Share (2021-2026)
Table 26. Rest of World Based Antibody-drug Conjugates Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Antibody-drug Conjugates Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Antibody-drug Conjugates Revenue Market Share (2021-2026)
Table 29. World Antibody-drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Antibody-drug Conjugates Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Antibody-drug Conjugates Market Size by Type (2027-2032) & (USD Million)
Table 32. World Antibody-drug Conjugates Market Size by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Table 33. World Antibody-drug Conjugates Market Size Value by Payload Mechanism (2021-2026) & (USD Million)
Table 34. World Antibody-drug Conjugates Market Size by Payload Mechanism (2027-2032) & (USD Million)
Table 35. World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Table 36. World Antibody-drug Conjugates Market Size Value by Drug-To-Antibody Ratio (2021-2026) & (USD Million)
Table 37. World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio (2027-2032) & (USD Million)
Table 38. World Antibody-drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Antibody-drug Conjugates Market Size by Application (2021-2026) & (USD Million)
Table 40. World Antibody-drug Conjugates Market Size by Application (2027-2032) & (USD Million)
Table 41. Daiichi Sankyo Company, Limited Basic Information, Manufacturing Base and Competitors
Table 42. Daiichi Sankyo Company, Limited Major Business
Table 43. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Product and Services
Table 44. Daiichi Sankyo Company, Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Daiichi Sankyo Company, Limited Recent Developments/Updates
Table 46. Daiichi Sankyo Company, Limited Competitive Strengths & Weaknesses
Table 47. Roche Basic Information, Manufacturing Base and Competitors
Table 48. Roche Major Business
Table 49. Roche Antibody-drug Conjugates Product and Services
Table 50. Roche Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Roche Recent Developments/Updates
Table 52. Roche Competitive Strengths & Weaknesses
Table 53. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 54. Pfizer Inc. Major Business
Table 55. Pfizer Inc. Antibody-drug Conjugates Product and Services
Table 56. Pfizer Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Pfizer Inc. Recent Developments/Updates
Table 58. Pfizer Inc. Competitive Strengths & Weaknesses
Table 59. Gilead Sciences, Inc. Basic Information, Manufacturing Base and Competitors
Table 60. Gilead Sciences, Inc. Major Business
Table 61. Gilead Sciences, Inc. Antibody-drug Conjugates Product and Services
Table 62. Gilead Sciences, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Gilead Sciences, Inc. Recent Developments/Updates
Table 64. Gilead Sciences, Inc. Competitive Strengths & Weaknesses
Table 65. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 66. Astellas Pharma Inc. Major Business
Table 67. Astellas Pharma Inc. Antibody-drug Conjugates Product and Services
Table 68. Astellas Pharma Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Astellas Pharma Inc. Recent Developments/Updates
Table 70. Astellas Pharma Inc. Competitive Strengths & Weaknesses
Table 71. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 72. AbbVie Inc. Major Business
Table 73. AbbVie Inc. Antibody-drug Conjugates Product and Services
Table 74. AbbVie Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. AbbVie Inc. Recent Developments/Updates
Table 76. AbbVie Inc. Competitive Strengths & Weaknesses
Table 77. GSK plc Basic Information, Manufacturing Base and Competitors
Table 78. GSK plc Major Business
Table 79. GSK plc Antibody-drug Conjugates Product and Services
Table 80. GSK plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. GSK plc Recent Developments/Updates
Table 82. GSK plc Competitive Strengths & Weaknesses
Table 83. ADC Therapeutics SA Basic Information, Manufacturing Base and Competitors
Table 84. ADC Therapeutics SA Major Business
Table 85. ADC Therapeutics SA Antibody-drug Conjugates Product and Services
Table 86. ADC Therapeutics SA Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. ADC Therapeutics SA Recent Developments/Updates
Table 88. ADC Therapeutics SA Competitive Strengths & Weaknesses
Table 89. Takeda Pharmaceutical Company Limited Basic Information, Manufacturing Base and Competitors
Table 90. Takeda Pharmaceutical Company Limited Major Business
Table 91. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Product and Services
Table 92. Takeda Pharmaceutical Company Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Takeda Pharmaceutical Company Limited Recent Developments/Updates
Table 94. Takeda Pharmaceutical Company Limited Competitive Strengths & Weaknesses
Table 95. AstraZeneca plc Basic Information, Manufacturing Base and Competitors
Table 96. AstraZeneca plc Major Business
Table 97. AstraZeneca plc Antibody-drug Conjugates Product and Services
Table 98. AstraZeneca plc Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. AstraZeneca plc Recent Developments/Updates
Table 100. AstraZeneca plc Competitive Strengths & Weaknesses
Table 101. Genmab A/S Basic Information, Manufacturing Base and Competitors
Table 102. Genmab A/S Major Business
Table 103. Genmab A/S Antibody-drug Conjugates Product and Services
Table 104. Genmab A/S Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Genmab A/S Recent Developments/Updates
Table 106. Genmab A/S Competitive Strengths & Weaknesses
Table 107. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 108. Johnson & Johnson Major Business
Table 109. Johnson & Johnson Antibody-drug Conjugates Product and Services
Table 110. Johnson & Johnson Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Johnson & Johnson Recent Developments/Updates
Table 112. Johnson & Johnson Competitive Strengths & Weaknesses
Table 113. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 114. Merck & Co., Inc. Major Business
Table 115. Merck & Co., Inc. Antibody-drug Conjugates Product and Services
Table 116. Merck & Co., Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Merck & Co., Inc. Recent Developments/Updates
Table 118. Merck & Co., Inc. Competitive Strengths & Weaknesses
Table 119. MacroGenics, Inc. Basic Information, Manufacturing Base and Competitors
Table 120. MacroGenics, Inc. Major Business
Table 121. MacroGenics, Inc. Antibody-drug Conjugates Product and Services
Table 122. MacroGenics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. MacroGenics, Inc. Recent Developments/Updates
Table 124. MacroGenics, Inc. Competitive Strengths & Weaknesses
Table 125. Sutro Biopharma, Inc. Basic Information, Manufacturing Base and Competitors
Table 126. Sutro Biopharma, Inc. Major Business
Table 127. Sutro Biopharma, Inc. Antibody-drug Conjugates Product and Services
Table 128. Sutro Biopharma, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Sutro Biopharma, Inc. Recent Developments/Updates
Table 130. Sutro Biopharma, Inc. Competitive Strengths & Weaknesses
Table 131. Heidelberg Pharma AG Basic Information, Manufacturing Base and Competitors
Table 132. Heidelberg Pharma AG Major Business
Table 133. Heidelberg Pharma AG Antibody-drug Conjugates Product and Services
Table 134. Heidelberg Pharma AG Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. Heidelberg Pharma AG Recent Developments/Updates
Table 136. Heidelberg Pharma AG Competitive Strengths & Weaknesses
Table 137. RemeGen Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 138. RemeGen Co., Ltd. Major Business
Table 139. RemeGen Co., Ltd. Antibody-drug Conjugates Product and Services
Table 140. RemeGen Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 141. RemeGen Co., Ltd. Recent Developments/Updates
Table 142. RemeGen Co., Ltd. Competitive Strengths & Weaknesses
Table 143. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 144. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Major Business
Table 145. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
Table 146. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recent Developments/Updates
Table 148. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 149. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 150. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Major Business
Table 151. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Product and Services
Table 152. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Recent Developments/Updates
Table 154. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Competitive Strengths & Weaknesses
Table 155. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 156. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Major Business
Table 157. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Product and Services
Table 158. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments/Updates
Table 160. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Competitive Strengths & Weaknesses
Table 161. Innovent Biologics, Inc. Basic Information, Manufacturing Base and Competitors
Table 162. Innovent Biologics, Inc. Major Business
Table 163. Innovent Biologics, Inc. Antibody-drug Conjugates Product and Services
Table 164. Innovent Biologics, Inc. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Innovent Biologics, Inc. Recent Developments/Updates
Table 166. Innovent Biologics, Inc. Competitive Strengths & Weaknesses
Table 167. CSPC Pharmaceutical Group Limited Basic Information, Manufacturing Base and Competitors
Table 168. CSPC Pharmaceutical Group Limited Major Business
Table 169. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Product and Services
Table 170. CSPC Pharmaceutical Group Limited Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 171. CSPC Pharmaceutical Group Limited Recent Developments/Updates
Table 172. CSPC Pharmaceutical Group Limited Competitive Strengths & Weaknesses
Table 173. Mabwell (Shanghai) Bioscience Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 174. Mabwell (Shanghai) Bioscience Co., Ltd. Major Business
Table 175. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Product and Services
Table 176. Mabwell (Shanghai) Bioscience Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Mabwell (Shanghai) Bioscience Co., Ltd. Recent Developments/Updates
Table 178. Mabwell (Shanghai) Bioscience Co., Ltd. Competitive Strengths & Weaknesses
Table 179. Lepu Biopharma Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 180. Lepu Biopharma Co., Ltd. Major Business
Table 181. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Product and Services
Table 182. Lepu Biopharma Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Lepu Biopharma Co., Ltd. Recent Developments/Updates
Table 184. Lepu Biopharma Co., Ltd. Competitive Strengths & Weaknesses
Table 185. Duality Biologics (Shanghai) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 186. Duality Biologics (Shanghai) Co., Ltd. Major Business
Table 187. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 188. Duality Biologics (Shanghai) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Duality Biologics (Shanghai) Co., Ltd. Recent Developments/Updates
Table 190. Duality Biologics (Shanghai) Co., Ltd. Competitive Strengths & Weaknesses
Table 191. MediLink Therapeutics (Suzhou) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 192. MediLink Therapeutics (Suzhou) Co., Ltd. Major Business
Table 193. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 194. MediLink Therapeutics (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 195. MediLink Therapeutics (Suzhou) Co., Ltd. Recent Developments/Updates
Table 196. MediLink Therapeutics (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
Table 197. GeneQuantum Healthcare (Suzhou) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 198. GeneQuantum Healthcare (Suzhou) Co., Ltd. Major Business
Table 199. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 200. GeneQuantum Healthcare (Suzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 201. GeneQuantum Healthcare (Suzhou) Co., Ltd. Recent Developments/Updates
Table 202. GeneQuantum Healthcare (Suzhou) Co., Ltd. Competitive Strengths & Weaknesses
Table 203. Hangzhou DAC Biotechnology Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 204. Hangzhou DAC Biotechnology Co., Ltd. Major Business
Table 205. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Product and Services
Table 206. Hangzhou DAC Biotechnology Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 207. Hangzhou DAC Biotechnology Co., Ltd. Recent Developments/Updates
Table 208. Hangzhou DAC Biotechnology Co., Ltd. Competitive Strengths & Weaknesses
Table 209. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 210. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Major Business
Table 211. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Product and Services
Table 212. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 213. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Recent Developments/Updates
Table 214. Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Competitive Strengths & Weaknesses
Table 215. Sichuan Biokin Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 216. Sichuan Biokin Pharmaceutical Co., Ltd. Major Business
Table 217. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Product and Services
Table 218. Sichuan Biokin Pharmaceutical Co., Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 219. Sichuan Biokin Pharmaceutical Co., Ltd. Recent Developments/Updates
Table 220. Sichuan Biokin Pharmaceutical Co., Ltd. Competitive Strengths & Weaknesses
Table 221. Bio-Thera Solutions, Ltd. Basic Information, Manufacturing Base and Competitors
Table 222. Bio-Thera Solutions, Ltd. Major Business
Table 223. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Product and Services
Table 224. Bio-Thera Solutions, Ltd. Antibody-drug Conjugates Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 225. Bio-Thera Solutions, Ltd. Recent Developments/Updates
Table 226. Bio-Thera Solutions, Ltd. Competitive Strengths & Weaknesses
Table 227. Global Key Players of Antibody-drug Conjugates Upstream (Raw Materials)
Table 228. Global Antibody-drug Conjugates Typical Customers
LIST OF FIGURES
Figure 1. Antibody-drug Conjugates Picture
Figure 2. World Antibody-drug Conjugates Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Antibody-drug Conjugates Total Revenue (2021-2032) & (USD Million)
Figure 4. World Antibody-drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Antibody-drug Conjugates Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 13. Antibody-drug Conjugates Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 16. World Antibody-drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 18. China Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 23. India Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Antibody-drug Conjugates by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Antibody-drug Conjugates Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Antibody-drug Conjugates Markets in 2025
Figure 27. United States VS China: Antibody-drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Antibody-drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Antibody-drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Antibody-drug Conjugates Market Size Market Share by Type in 2025
Figure 31. HER2-Directed ADCs
Figure 32. TROP2-Directed ADCs
Figure 33. Hematologic-Lineage Antigen ADCs
Figure 34. Other Target Antigen ADCs
Figure 35. World Antibody-drug Conjugates Market Size Market Share by Type (2021-2032)
Figure 36. World Antibody-drug Conjugates Market Size by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 37. World Antibody-drug Conjugates Market Size Market Share by Payload Mechanism in 2025
Figure 38. Topoisomerase I Inhibitor ADCs
Figure 39. Microtubule Inhibitor ADCs
Figure 40. DNA-Damaging ADCs
Figure 41. Other Payload ADCs
Figure 42. World Antibody-drug Conjugates Market Size Market Share by Payload Mechanism (2021-2032)
Figure 43. World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Figure 44. World Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio in 2025
Figure 45. DAR Up To 4
Figure 46. DAR Above 4 And Below 8
Figure 47. DAR 8 And Above
Figure 48. Other
Figure 49. World Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio (2021-2032)
Figure 50. World Antibody-drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Antibody-drug Conjugates Market Size Market Share by Application in 2025
Figure 52. Breast and Gynecologic Malignancies
Figure 53. Lung and Other Thoracic Malignancies
Figure 54. Other Solid Tumors
Figure 55. Hematologic Malignancies
Figure 56. World Antibody-drug Conjugates Market Size Market Share by Application (2021-2032)
Figure 57. Antibody-drug Conjugates Industrial Chain
Figure 58. Methodology
Figure 59. Research Process and Data Source
Figure 1. Antibody-drug Conjugates Picture
Figure 2. World Antibody-drug Conjugates Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Antibody-drug Conjugates Total Revenue (2021-2032) & (USD Million)
Figure 4. World Antibody-drug Conjugates Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Antibody-drug Conjugates Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Antibody-drug Conjugates Revenue (2021-2032) & (USD Million)
Figure 13. Antibody-drug Conjugates Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 16. World Antibody-drug Conjugates Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 18. China Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 23. India Antibody-drug Conjugates Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Antibody-drug Conjugates by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Antibody-drug Conjugates Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Antibody-drug Conjugates Markets in 2025
Figure 27. United States VS China: Antibody-drug Conjugates Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Antibody-drug Conjugates Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Antibody-drug Conjugates Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Antibody-drug Conjugates Market Size Market Share by Type in 2025
Figure 31. HER2-Directed ADCs
Figure 32. TROP2-Directed ADCs
Figure 33. Hematologic-Lineage Antigen ADCs
Figure 34. Other Target Antigen ADCs
Figure 35. World Antibody-drug Conjugates Market Size Market Share by Type (2021-2032)
Figure 36. World Antibody-drug Conjugates Market Size by Payload Mechanism, (USD Million), 2021 & 2025 & 2032
Figure 37. World Antibody-drug Conjugates Market Size Market Share by Payload Mechanism in 2025
Figure 38. Topoisomerase I Inhibitor ADCs
Figure 39. Microtubule Inhibitor ADCs
Figure 40. DNA-Damaging ADCs
Figure 41. Other Payload ADCs
Figure 42. World Antibody-drug Conjugates Market Size Market Share by Payload Mechanism (2021-2032)
Figure 43. World Antibody-drug Conjugates Market Size by Drug-To-Antibody Ratio, (USD Million), 2021 & 2025 & 2032
Figure 44. World Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio in 2025
Figure 45. DAR Up To 4
Figure 46. DAR Above 4 And Below 8
Figure 47. DAR 8 And Above
Figure 48. Other
Figure 49. World Antibody-drug Conjugates Market Size Market Share by Drug-To-Antibody Ratio (2021-2032)
Figure 50. World Antibody-drug Conjugates Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 51. World Antibody-drug Conjugates Market Size Market Share by Application in 2025
Figure 52. Breast and Gynecologic Malignancies
Figure 53. Lung and Other Thoracic Malignancies
Figure 54. Other Solid Tumors
Figure 55. Hematologic Malignancies
Figure 56. World Antibody-drug Conjugates Market Size Market Share by Application (2021-2032)
Figure 57. Antibody-drug Conjugates Industrial Chain
Figure 58. Methodology
Figure 59. Research Process and Data Source
